• The Science of ENBREL
  • Years of Experience
  • Proven Efficacy

The Attributes of ENBREL

ENBREL blocks the activity of excess active tumor necrosis factor (TNF) to reduce the inflammation that causes psoriatic lesions and joint pain.

Infections, including serious infections, some fatal, have been observed in patients treated with ENBREL.

Learn more

Confidence in Experience

ENBREL has more than 2.8 million patient-years of worldwide postmarketing experience.1*†

Learn more

* Based on estimated number of patient-years from 1998 through May 2011. As of May 2011, estimated patient-years is 2,845,000. Estimated number of patient-years is calculated by region based on the number of ENBREL units distributed and an estimated average dose.

† Based on year of FDA approval.

‡ In the EASE trial, an open-label study, psoriasis patients who took ENBREL 50 mg twice weekly (BIW) for 3 months (N = 2,546) were asked: "In the past week, how satisfied are you with your psoriasis therapy in general?" The four possible responses, ranging from highest to lowest satisfaction, were "very much," "a lot," "a little," or "not at all." 78% of patients who responded chose either "very much" or "a lot" at 3 months. At baseline prior to ENBREL therapy, ~ 1 out of 10 plaque psoriasis patients were highly satisfied with their therapy.

1,2
From the EASE trial

Rapid and Sustained Long-term Efficacy1,3-5

In adult moderate to severe plaque psoriasis, ENBREL has demonstrated rapid and sustained long-term efficacy for up to 132 weeks in the pivotal plaque psoriasis clinical trials and an open-label extension trial.

Learn more

Support for Patients

I called 1-888-4ENBREL and a nurse helped me feel more comfortable with the injection process."
ENBREL offers you and your patients support you can count on. Discover the wide variety of resources available through ENBREL Support™.

Learn more



 

Supportive data

Moderate to Severe Plaque Psoriasis
In medical studies, nearly half of patients saw a significant improvement in their plaque psoriasis within 3 months of using ENBREL. Overall, 3 out of 4 patients saw improvement. ENBREL can work fast; many patients saw improvement within 2 months.

Psoriatic Arthritis
In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients who used it. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.

Indications

Plaque Psoriasis
ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Psoriatic Arthritis
ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

Initiate Prior Authorizations

Submit prior authorizations online. Register today for access to ENBREL Prior Auth Assist.

Sign up today for ENBREL Prior Auth Assist.
Or
Prescribed by nearly 11,000 dermatology professionals in the US.1‡

1. Data on file, Amgen.

§ Dermatologists, nurse practitioners, physician's assistants in dermatology offices, and dermatology subspecialists, which include D, DS, DMP, PDD, and some NP, PA, and IM/PCPs. Based on cumulative data from 2003 through May 2011.

When Brent's plaque psoriasis symptoms worsened, he felt isolated and stopped going out with friends.

Brent asked his doctor about ENBREL.

"I feel more comfortable in my skin."


Supportive data

Moderate to Severe Plaque Psoriasis
In medical studies, nearly half of patients saw a significant improvement in their plaque psoriasis within 3 months of using ENBREL. Overall, 3 out of 4 patients saw improvement. ENBREL can work fast; many patients saw improvement within 2 months.

Psoriatic Arthritis
In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients who used it. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.

Home
Close